Skip to content

A multi-center, randomized, controlled trial for Tailinfang in the treatment of recurrent urinary tract infection

A multi-center, randomized, controlled trial for Tailinfang in the treatment of recurrent urinary tract infection

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018350
Enrollment
Unknown
Registered
2018-09-12
Start date
2018-09-17
Completion date
Unknown
Last updated
2018-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent urinary tract infection

Interventions

Group 1:Tailinfang
Group 2:Bacteriostatic therapy

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Agree to sign informed consent form; 2. Aged 18 to 75 years old, male or female; 3. Meet the diagnostic criteria for recurrent urinary tract infection; 4. Urinary tract infection occurred more than 2 times within half a year or more than 3 times within 1 year, with a history of more than 2 years; 5. 2 weeks after using sensitive antibacterial therapy in the stable phase of recurrent urinary tract infection or during acute attack; 6. Comply with the diagnosis and syndrome differentiation standard of Chinese medicine Laolin (Deficiency of Spleen and Kidney, with damp heat flow).

Exclusion criteria

Exclusion criteria: 1. Acute pyelonephritis or first-episode acute urinary tract infection; 2. Imaging examination of congenital malformations of urinary tract, stones, water and other diseases; 3. Urethral syndrome; 4. Chronic kidney disease that eGFR<<30ml/(min·1.73m2); 5. Pregnancy or breastfeeding woman; 6. People Have allergies or allergies to two drugs; 7. Serious damage to heart, liver, kidney function or other serious underlying diseases such as diabetes; 8. Severe central nervous system disease; 9. Those who are participating in other drug clinical trials or participate in other clinical trials in China within 3 months.

Design outcomes

Primary

MeasureTime frame
Urine routine;Mid-stage urine culture;the syndrome scores of TCM;Renal function;Liver function;

Countries

China

Contacts

Public ContactGong Xuezhong

Shanghai Municipal Hospital of Traditional Chinese Medicine

shnanshan@hotmail.com+86 18116070658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026